Other agents (metformin, glibenclamide (glyburide), glimepiride, gliclazide, exenatide, liraglutide, alpha glucosidase inhibitors, and SGLT2 inhibitors) are not recommended particularly in people with moderate to severe CKD (eGFR <45–60 mL/min/1.73 m2) because their efficacy is reduced and/or the risks of hypoglycemia or other adverse events are increased. The gene discussed is GAA; the disease is Hypoglycemia.